

# Clinical study of a range of soft contact lens brands

|  |   |   |
|--|---|---|
| <b>Submission date</b><br>09/08/2024   | <b>Recruitment status</b><br>Recruiting   | <input type="checkbox"/> Prospectively registered<br><input type="checkbox"/> Protocol                                  |
| <b>Registration date</b><br>16/08/2024 | <b>Overall study status</b><br>Ongoing    | <input type="checkbox"/> Statistical analysis plan<br><input type="checkbox"/> Results                                  |
| <b>Last Edited</b><br>29/12/2025       | <b>Condition category</b><br>Eye Diseases | <input type="checkbox"/> Individual participant data<br><input checked="" type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

### Background and study aims

The aim of this study is to confirm the current safety and effectiveness of sphere, toric, and multifocal lenses compared to similar marketed devices and to address the long-term safety and performance of daily wear in users of these lenses. The choice of lenses was made to assess the clinical performance of the test lenses against currently marketed state-of-the-art products for the same indication.

### Who can participate?

Patients aged between 8 and 75 years old who are current wearers of CE-marked CooperVision test or control lenses. Equivalent private-label contact lenses can be included in either group (for at least 6 months)

### What does the study involve?

The participants will attend the clinic for one study visit wearing the study test or control lenses. The visit will be about 2 hours long during which participants will complete a questionnaire, have their vision measured, the contact lens fit evaluated, and their eyes examined. In addition, the investigator will review participant clinical notes available at the practice site to identify any adverse events associated with wearing study test or control lenses.

### What are the possible benefits and risks of participating?

There may not be direct benefits to the participants, but participation may contribute to scientific information that may be used in the development of new contact lens products. The knowledge gained from this study may lead to important conclusions regarding the real-world safety and effectiveness of these lenses. The potential risks are minimal so the benefit-risk ratio is acceptable. Participants will already be routinely wearing these lenses so this is considered a non-significant risk study. Routine non-invasive procedures will be conducted in this study.

### Where is the study run from?

EuroLens (UK)

### When is the study starting and how long is it expected to run for?

December 2023 to April 2026

Who is funding the study?  
CooperVision Inc., Ltd (USA)

Who is the main contact?  
1. Archana Binod-Nair, archana.binod-nair@coopervision.co.uk  
2. Sandhya Shekar, Sandhya.Shekar@coopervision.co.uk

## Contact information

### Type(s)

Public

### Contact name

Mrs Archana Binod-Nair

### Contact details

CooperVision, R&D Facility, 36 School Lane, Chandler's Ford  
Eastleigh  
United Kingdom  
SO53 4LY  
+44 (0)7974 858 818  
archana.binod-nair@coopervision.co.uk

### Type(s)

Scientific

### Contact name

Miss Sandhya Shekar

### Contact details

CooperVision, R&D Facility, 36 School Lane, Chandler's Ford  
Eastleigh  
United Kingdom  
SO53 4LY  
+44 (0)7974899374  
Sandhya.Shekar@coopervision.co.uk

### Type(s)

Principal investigator

### Contact name

Prof Philip Morgan

### Contact details

EuroLens Research  
The University of Manchester  
Manchester  
United Kingdom

M13 9PL  
+44 (0)161 306 4441  
philip.morgan@manchester.ac.uk

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number

CV-23-91

## Study information

### Scientific Title

This study aims to assess the post-market safety and performance of a range of contact lens types

### Study objectives

The objective of this post-market study is to demonstrate acceptable safety and effectiveness (performance) of a range of CooperVision soft contact lens types compared with similar marketed devices, when used in the general population.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

approved 02/07/2024, University Research Ethics Committees (URECs) (2nd Floor, The Christie Building, The University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom; +44 (0)161 306 6000; urec1@manchester.ac.uk), ref: 2024-20572-36344

### Study design

Prospective single-visit open-label observational study

### Primary study design

Observational

### Study type(s)

Efficacy, Safety

### Health condition(s) or problem(s) studied

Myopia, astigmatism, hyperopia, presbyopia

### Interventions

Recruitment:

Subjects will be recruited from the site's own patient listings based in England and Scotland.

### Consenting:

Informed consent shall be obtained in writing from adult subjects, as well as assent and parental permission/consent from minors and their parent or legal guardian. The process shall be performed by an appropriately trained/delegated study member and will be documented before any procedure specific to the clinical investigation is carried out. The study members will be trained in the conduct of clinical research, show willingness to follow the study protocol and will be trained in GCP and the study protocol before commencing the study.

The potential participant will attend the clinic for one study visit wearing the study test or control lenses. The visit will be about 2 hours long during which participants will be consented to participate in the study, complete a questionnaire, have their vision measured, the contact lens fit evaluated, and their eyes examined. In addition, the investigator will review participant clinical notes available at the practice site to ensure that any adverse events associated with wearing study tests or control lenses that may have occurred are identified and analysed.

Please find below a list of the contact lenses 'or similar' tested:

Avaira Vitality Sphere  
Proclear Sphere  
Biomedics 55 Asphere  
Biomedics Now Sphere  
Avaira Vitality Toric  
Proclear Toric and Toric XR  
Biomedics Toric  
Proclear Multifocal and Multifocal XR  
Proclear Multifocal Toric  
Clariti 1 day Daily Disposable Sphere  
Biomedics 1 Day Extra-1 Day Sphere  
Proclear - 1 Day – Sphere  
Live 1 day  
Clariti 1 day Daily Disposable Toric  
Biomedics 1 Day Toric and EXTRA Toric  
Clariti 1 day Daily Disposable Multifocal  
Proclear 1 Day Multifocal

The acceptance and performance of the contact lenses will be tested for efficacy as per ISO11980-2012:

1. Measurement of contact lens logMAR visual acuity
2. Subjective rating of comfort, vision and handling
3. Subjective rating of contact lens fit and contact lens surface characteristics

The performance will be tested for safety as per ISO11980-2012:

1. Identification of ocular adverse events related to contact lens wear
2. Measurement of spectacle logMAR visual acuity
3. Assessment of the ocular tissues and ratings as per ISO11980-2012 scales

### Intervention Type

Device

### Phase

Not Applicable

**Drug/device/biological/vaccine name(s)**

Range of soft contact lens brands

**Primary outcome(s)**

1. Visual performance (visual acuity) measured based on high-contrast visual acuity at one timepoint
2. Incidence of contact lens-related adverse events measured using subject reports and slit lamp evaluation

**Key secondary outcome(s)**

Relationship determination between lens fit, surface measurements, and subjective scores measured using appropriate statistical modeling, slit lamp evaluation, and VAS/ISO Questionnaires at one timepoint

**Completion date**

30/04/2026

## **Eligibility**

**Key inclusion criteria**

1. Age 8 to 75 years (inclusive)
2. They understand their rights as a research subject and are willing to sign a Statement of Informed Consent
3. Current wearer (for at least 6 months) of CE-marked CooperVision test or control lenses. Equivalent private-label contact lenses can be included in either group

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

8 years

**Upper age limit**

75 years

**Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

Participation in a contact lens or contact lens care product clinical trial within the previous 30 days

**Date of first enrolment**

01/08/2024

**Date of final enrolment**

30/04/2026

## Locations

**Countries of recruitment**

United Kingdom

England

Scotland

**Study participating centre****EuroLens Research**

The University of Manchester

Oxford Road

Manchester

England

M13 9PL

## Sponsor information

**Organisation**

CooperVision Inc Ltd

## Funder(s)

**Funder type**

Industry

**Funder Name**

CooperVision

**Alternative Name(s)**

CooperVision, Inc., CooperVision Inc, CooperVision Inc., CooperVision, Inc

**Funding Body Type**

Government organisation

**Funding Body Subtype**  
For-profit companies (industry)

**Location**  
United States of America

## Results and Publications

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**  
Not expected to be made available

**Study outputs**

| Output type                                   | Details                       | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|-------------------------------|--------------|------------|----------------|-----------------|
| <a href="#">Participant information sheet</a> | Participant information sheet | 11/11/2025   | 11/11/2025 | No             | Yes             |